Natco slumps on Teva's Copaxone appeal
Apr 01 2014 , Mumbai
The appeal could deter generic manufacturers such as Natco from introducing cheaper versions of Capaxone onto the market as soon as May.
The company continues to believe that Teva's patent on Copaxone is "invalid," the company said in a filing to the exchange.
Natco shares had earlier fallen as much as 18.6 percent.